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Objectives: To gain insights into the usage of factor VIII (FVIII) products by patients diagnosed 
with moderate/severe hemophilia A, and to assess the impact and perceived importance of 
product storage.
Methods: In this study, 200 patients diagnosed with moderate or severe hemophilia A across 
seven countries participated. Data were collected via a 30-minute, face-to-face interview in six 
countries and via a web-based survey in the seventh country. The questionnaire evaluated the 
effect of six features associated with FVIII products on the choice of the product; the structure 
and flow of data collection was designed to eliminate potential bias.
Results: Two-thirds of the respondents were using recombinant FVIII products. Only 17% 
were generally dissatisfied with current FVIII products, whereas 40% of the respondents 
were dissatisfied with frequency of administration and storage issues when traveling. The 
majority noted restrictions in their daily activities, particularly travel and sports. Most of them 
(85%), stored their product in the refrigerator and of these, 88% believed that it should always 
be stored there. These patients were also less satisfied with the product overall, more concerned 
about storage temperature, more restricted in daily activities, and spent more time on preparation 
and injection compared with patients who stored their product at room temperature. Conjoint 
analysis revealed that origin of FVIII (plasma-derived vs recombinant) was the strongest 
driver of product choice among all respondents, followed by storage flexibility (temperature), 
reconstitution device, and administration frequency. In this study, we did not investigate the 
efficacy and safety of the product.
Conclusion: Not refrigerating FVIII products was associated with greater patient satisfac-
tion and less restriction on daily activities. If efficacy and safety are unaffected, then storing 
FVIII at room temperature might have a positive impact on product choice. Few patients were 
aware that FVIII can be stored without refrigeration, suggesting that health care professionals 
who treat hemophilia should communicate this aspect to the patient (depending on the labeled 
option); this approach might offer patients greater flexibility when traveling and require less 
time for reconstitution.
Keywords: hemophilia A, recombinant FVIII, plasma-derived FVIII, storage, reconstitution, 
stability
Plain language summary
This study was performed to help understand how real-life use and ease of storage affect the 
choice of treatment product (factor VIII) for patients with hemophilia A. Feedback was col-
lected from 200 patients across seven countries using face-to-face interviews and a web-based 
survey. Only 17% of the patients were found to be dissatisfied overall with their treatment 
product, whereas over 40% of the patients were found to be dissatisfied with how often their 
treatment product needed to be taken and with ease of storage when traveling. Many patients 
thought that using their treatment product interfered with daily activities, including travel 
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and sports. The treatment product origin (recombinant or plasma-
derived factor VIII) was considered most important for the choice 
of the treatment, followed by ease of storage, ease of handling, and 
how often the treatment needed to be taken. Patients preferred not 
having to refrigerate FVIII products and those that did were less 
satisfied with the product overall. Many patients were not aware 
that FVIII products can be stored at room temperature. This needs 
to be better communicated to patients by health care professionals 
treating hemophilia.
Introduction
Hemophilia A is an X-linked recessive inherited bleed-
ing disorder characterized by the deficiency of clotting 
factor VIII (FVIII). In the severe form of hemophilia, there 
is a high risk of spontaneous bleeding in joints, muscles, or 
soft tissues.1 Patients with severe hemophilia A are known 
to benefit from prophylactic treatment,2 and most patients 
administer intravenous FVIII twice or thrice a week to pre-
vent spontaneous bleeding. The remainder of the patients 
treat on-demand, which means that they administer FVIII 
only to stop bleeding.3,4 Benefits of adherence to prophy-
laxis among patients with severe hemophilia have been well 
demonstrated.3 However, treatment practice varies greatly 
between countries, and access to hemophilia care is still not 
uniform worldwide.5,6
FVIII is administered by an intravenous injection, usually 
by the patient or by their caregivers. Prior to the injection, 
the FVIII concentrate, which is a lyophilized powder, must 
be reconstituted by mixing it with a diluent in multiple steps. 
Manufacturers recommend storing FVIII in a refrigerator and 
reconstituting the product at room temperature. However, 
most FVIII products can be stored at room temperature, with 
a limited shelf-life ranging from 3 to 12 months depending 
on the brand.
A review of the available literature regarding clinical 
trials evaluating the efficacy of FVIII and factor IX products 
or bypassing agents demonstrated an overall improvement 
in health-related quality of life with prophylactic treatment 
in hemophilia.7 However, the inconvenience of reconstitut-
ing and administering FVIII injections may have a negative 
impact on the daily life of the patient, thus creating a barrier 
to patient adherence to medication.8,9 Furthermore, storing 
the FVIII concentrate in the refrigerator is an additional 
inconvenience. Although most FVIII products remain stable 
at room temperature up to 25°C for a limited time, patients 
may worry about its stability when traveling and interrupting 
the cool chain. Carrying all items required for reconstitu-
tion and limited space in the refrigerator create additional 
inconveniences on trips. As patients with hemophilia have 
become more mobile, in line with our increasingly mobile 
society,10 it is reasonable to assume that the flexibility of 
storing FVIII concentrates without refrigeration might be an 
important patient requirement to be addressed.11
A recent study in a different therapeutic area, growth hor-
mone therapy, showed that patients prefer a storage-flexible 
product when they have the choice, and that growth hormone 
products that are stable at room temperature are associated 
with shorter injection times, greater patient adherence to 
medication, less wastage, and fewer restrictions of daily 
activities due to difficulties with injections.12 Recent studies 
on patients with hemophilia A investigated frequency of 
administration, type of reconstitution device, out-of-pocket 
costs, treatment side effects, efficacy (annual bleeding rate), 
diluent volume, number of vials per infusion, and experience 
of manufacturer as criteria for patients’ preference.8,13–15 
It can be summarized from these studies that efficacy (annual 
bleeding rate in prophylactic treatment) and frequency of 
administration (2–3×/week vs 1×/week vs 1×/2 weeks) had 
a high impact on patients’ treatment preference. However, 
the aforementioned studies evaluating patient preferences in 
hemophilia A have not investigated the importance of stor-
age flexibility (ie, the possibility of storage with or without 
refrigeration) to the same extent as other product features.
Thus, the following were the aims of this study: first, to 
provide reliable patient insights on real-life use of FVIII prod-
ucts and to find the association between FVIII storage con-
ditions, daily life activities, satisfaction with treatment, and 
unmet needs. Second, to investigate the relative importance 
of storage flexibility compared with other product features.
Methods
This study was conducted in seven countries in three 
regions – Europe (France, Italy, and UK), Latin America 
(Argentina, Brazil, and Mexico), and Japan – through a struc-
tured questionnaire that took ~30 min to complete. Individual 
interviews were conducted face-to-face using computer-
assisted personal interviewing in all countries except Japan, 
where data were collected via a web-based survey.
The questionnaire comprised five sections: current use 
of FVIII products, satisfaction with current treatment, unmet 
needs, product preference, and demographics. In all but 
the product preference section, patients were tasked with 
responding to a mixture of simple closed questions, rating 
scales, and open-ended questions.
The product preference section was more complex and 
designed to investigate the importance of individual product 
attributes in relation to product choice. Conjoint analysis, a 
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well-established method that provides in-depth understanding 
of which product attributes are valued most highly by respon-
dents and which are most likely to drive product choice was 
chosen for this study.
Patients were presented with scenarios showing hypo-
thetical product profiles covering six attributes (origin of 
FVIII, storage flexibility [temperature], storage flexibility 
[shelf life], reconstitution device, stability out of refrigerator 
after mixing, and frequency of administration in prophylaxis) 
for three different FVIII products. Patients were asked to 
indicate which of the three products they preferred. Based on 
the observed likelihood of choosing a product with a given 
attribute level, for each attribute and level, its value (utility 
score) was calculated. Table 1 shows the six product attri-
butes and their levels used in defining FVIII products.
In all, 16 randomized scenarios were presented to each 
patient. Table 2 shows one of these randomly generated sce-
narios describing three products in one of the choice tasks. 
Patients were told to assume that all three products were 
identical to each other and to their current FVIII product in 
terms of efficacy and safety.
Based on the product selected in each scenario, the contri-
bution of each attribute to product choice was measured. For 
each attribute, the contribution was the part-worth associated 
to the level describing the products in the conjoint scenarios. 
Part-worth utilities measure how valuable each attribute level 
is (eg, 2×/week administration) relative to the other levels 
(eg, 3×/week administration). The primary outcome of 
conjoint analysis is the estimation of the part-worth utili-
ties associated to each level of each attribute describing the 
products in the conjoint design.
Four pilot interviews were conducted in London, UK, 
in an interviewing facility to verify that all questions were 
easily understood. Thereafter, all remaining face-to-face 
interviews in Europe and Latin America were conducted at a 
location chosen by the individual patient (average interview 
duration: 30 min).
Before initiating recruitment and interviewing patients, 
the design and the methodology were submitted to the 
institutional review board (IRB) of the Freiburger Ethik-
Kommission. After reviewing the study protocol, the IRB 
granted approval on May 9, 2016.
statistical analysis
Descriptive statistics were used to summarize responses to the 
individual questions. Subgroup comparisons (eg, differences 
between patient subgroups) were analyzed with a chi-square 
test for nominal data or two-independent samples t-tests to 
compare means of a normally distributed, interval-dependent 
variable for two independent groups.
Table 1 Product characteristics (attributes) and levels to create hypothetical FVIII product profiles
Attributes Levels
Origin of FViii (1) FViii made from human blood plasma
(2) Plasma-free/recombinant (FViii made completely in a laboratory with DnA technology)
Storage flexibility (temperature) (1) needs to be stored in the refrigerator at 2°c–8°c (~10 min until it reaches room temperature 
before you can inject it)
(2) can be stored anywhere outside the refrigerator at 25°c
(3) can be stored anywhere outside the refrigerator at 30°c
(4) can be stored anywhere outside the refrigerator at 40°c
Storage flexibility (shelf life): 
Maximum storage time at this 
temperature out of the refrigeratora
(1) can be stored for 3 months
(2) can be stored for 6 months
(3) can be stored for 9 months
(4) can be stored for 12 months
reconstitution device (mixing FViii 
powder with solvent)
(1) Mix FVIII in a prefilled syringe with both powder and solvent enclosed in separate chambers of the 
same syringe
(2) Mix FVIII powder with a solvent in a prefilled syringe. The syringe is connected with the vial 
containing FViii
(3) Mix FViii with two connected vials. One vial contains FViii powder, and the other contains solvent. 
Then put the mixed factor into a syringe connected with the vials
stability out of refrigerator after 
mixing (in case of unexpected 
interruptions)
(1) 2 hours
(2) 3 hours
(3) 4 hours
Frequency of administration in 
prophylaxis
(1) 2×/week
(2) 3×/week
Note: aShown only if Level 2, 3, or 4 is shown for attribute “storage flexibility (temperature)”.
Abbreviations: DnA, deoxyribonucleic acid; FViii, factor Viii.
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sample
The survey was completed by 200 adult males between June 
and August 2016 across seven countries: Argentina, Brazil, 
France, Italy, Mexico, and UK (30 samples in each), and 
Japan (20 samples).
Eligible patients were between 18 and 75 years of age, 
diagnosed with moderate or severe hemophilia A by a physi-
cian, and currently using a FVIII product.
Patients were recruited locally by health care professionals 
treating hemophilia A (77 patients), through existing patient 
contacts available at local health research agencies conducting 
interviews in hemophilia A (79 patients) and through local 
patient associations (44 patients). Patients provided written, 
informed consent before participating in the study. Interviews 
were conducted either at the patient’s home (111 patients), at 
a central facility such as the office of the local research agency 
(69 patients), or via the internet (20 patients, in Japan only).
characteristics of the study population
Demographic characteristics
There was a broad representation of age groups among the 
patients; 34% were in the age group of 18–30 years, 22% were 
in the age group of 31–40 years, and 25% were in the age 
group of 41–50 years, and rest of the patients were in the age 
group of 51–75 years. The average age was 38 years. Over half 
of the patients (57%) had attended either secondary school or 
high school; over one-third of the patients (39%) had entered 
university. Most of the patients (68%) were working with 
one-third of the total sample involved in “office work”.
clinical characteristics
Most of the 200 patients (71%) had a diagnosis of severe 
hemophilia A. Just over half of the patients (51%) had received 
their diagnosis at or shortly after birth, and a further 33% of 
the patients received their diagnosis between the ages of 1 and 
2 years, resulting in an average age of diagnosis of 1.4 years.
FViii treatment characteristics
About one-quarter (26%) of the patients had been using their 
current FVIII product for 11 years. Overall, the average 
length of time for current FVIII product use was just 8 years. 
Overall, twice as many patients were being treated with 
recombinant FVIII products compared with plasma-derived 
FVIII products (67% vs 33%, respectively). In Europe, sig-
nificantly more patients used recombinant FVIII products 
(93%) compared with Latin America (40%; p0.001); 
the proportion of patients using recombinant products in 
Japan was 70%. Prophylactic treatment was more common 
than on-demand treatment (74% vs 27%, respectively). 
The frequency of injection differed markedly between the 
Table 2 example scenario of the trade-off exercise
Example scenario Product K Product L Product M
Origin of FViii Plasma-free/recombinant (FViii 
made completely in a laboratory 
with DnA technology)
FViii made from human blood plasma Plasma-free/recombinant (FViii 
made completely in a laboratory 
with DnA technology)
Storage flexibility (temperature) can be stored anywhere outside 
the refrigerator at 30°c
can be stored anywhere outside the 
refrigerator at 30°c
needs to be stored in the 
refrigerator at 2°c–8°c (~10 min 
until it reaches room temperature 
before you can inject it)
Storage flexibility (shelf life) 12 months 6 months
reconstitution device (mixing 
FViii powder with solvent)
Mix FViii powder with a solvent 
in a prefilled syringe. The syringe 
is connected with the vial 
containing FViii
Mix FViii with two connected vials. 
One vial contains FViii powder, and 
the other contains solvent. Then, 
take the mixed factor in a syringe 
connected with the vials
FVIII in a prefilled syringe 
with both powder and solvent 
enclosed in separate chambers 
of the same syringe
stability outside the refrigerator 
after mixing (in case of 
unexpected interruptions)
4 hours 3 hours 2 hours
Frequency of administration in 
prophylaxis
2×/week 3×/week 3×/week
Notes: Question as framed to responders: “Please imagine that your FViii product is no longer available. Your doctor presents and recommends three alternative products 
that are approved for the treatment of hemophilia A. Both efficacy and safety are absolutely identical and comparable with the product you currently use. All three products 
can be used for prophylaxis (on a regular basis) or on-demand (only occasionally as needed, depending on expected activity level or to treat bleeds)”
Abbreviations: DnA, deoxyribonucleic acid; FViii, factor Viii.
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two groups; patients using FVIII products prophylactically 
complied reasonably well with the thrice weekly dosage 
recommendation, injecting on an average of 2.7 times per 
week. On-demand users injected much less frequently, just 
over twice a month on an average.
Travel behavior
Patients in the study tended to travel reasonably frequently, 
but mostly for short periods. On an average, they traveled 
10.4 times per year, staying away from home for 1 night. 
“A weekend/one or two nights away” occurred on average 
6.4 times a year. In contrast, patients were much less likely 
to travel away from home for longer periods (2.7×/year 
for 2 days, 1 week at a time; 1.3×/year for 1 week 
at a time).
leisure activities
Seventy-six percent of the patients with hemophilia A were 
found to be actively engaged in physical activities, of which 
walking was the most common (46%). Swimming was also 
a popular activity (42%), followed by gymnastics (18%) 
and jogging (14%). All patients took part in social activities, 
especially meeting friends and visiting the cinema.
Results
Usage and administration of current FViii 
products
Patients using prophylactic treatment (74% of the sample) 
stated that most injections (88%) were administered at 
home. While 19% of the patients on prophylaxis treatment 
did not have a specific time of day for the administration of 
an injection, 26% of the patients claimed to administer it 
“when they get up” and 26% “between breakfast and noon”. 
The remainder of the patients injected “in the evening” or 
“before going to bed”.
Users of prophylactic treatment broadly complied with 
the most often recommended treatment regimen of three 
injections per week; over half of the patients (56%) fully 
complied, and a small percentage (8%) injected four times 
or more per week. However, almost one-third of the patients 
(29%) injected only twice per week, giving an overall average 
of 2.7 injections per week.
A high percentage (85%) of patients stored their FVIII 
product in the refrigerator, whereas the remainder of the 
patients stored it at room temperature. Just under two-thirds 
(130 of 200) of the patients stored their FVIII product in their 
refrigerator alongside groceries, whereas about one-fifth of 
the patients stored it in a refrigerator dedicated to medicines. 
This latter approach was most common in Latin America, 
where 28% of the patients used dedicated refrigerators for 
storage compared with 20% in Japan and 13% in Europe.
There were regional and local differences with regard 
to “storage outside the refrigerator at room temperature” 
(Table 3). For instance, while 52% of the patients sampled 
in the UK stored the product outside the refrigerator, none of 
the patients surveyed in Latin America or Italy adopted this 
practice. No statistically significant differences were observed 
in any other demographic factors between patients who 
stored their FVIII product inside or outside the refrigerator.
Patients storing FViii in the refrigerator
Most of the patients (88%) who stored FVIII in the 
refrigerator believed that FVIII products must be stored “in 
the fridge at all times”. Of the remaining 12% of the patients 
who did not believe this, the majority (76%) believed that the 
maximum time a FVIII product could be stored outside the 
refrigerator was around 1–3 months; only 5% believed that 
a FVIII product could be stored outside the refrigerator for 
7–12 months.
Frequency of travel was closely associated with stor-
age behavior. Patients storing FVIII mainly outside the 
refrigerator traveled on an average 16 times per year, which is 
significantly higher than the travel frequency of patients who 
stored FVIII mainly in the refrigerator (9 travels per year; 
p0.01; t-test). Most of the patients who normally stored 
their FVIII product in the refrigerator at home continued to 
keep it cool when staying at a hotel (93%) or when away 
from home for leisure activities (76%). Likewise, 92% of the 
patients who stored their FVIII product at room temperature 
at home continued to do so while traveling.
Storage temperature was a concern for many patients in 
the subgroup of 169 patients who mainly stored their FVIII 
product in the refrigerator. Of these patients, 79% reported 
worrying at least sometimes (~17 times per year) about the 
Table 3 countries and regions of origin for patients storing their 
FViii product in or outside the refrigerator
Country/ 
region
Storing FVIII in the  
refrigerator (n=169)
Storing FVIII outside 
refrigerator (n=31)
France 13% 26%
italy 18% 0%
UK 8% 52%
Argentina 18% 0%
Brazil 18% 0%
Mexico 18% 0%
Japan 8% 23%
Total 100% 100%
Abbreviation: FViii, factor Viii.
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storage temperature. Notably, patients in Latin America 
(n=90) worried more often about storage temperatures 
(~24 times per year) compared with patients in Europe or 
Japan (~9 times per year; p0.001).
Nearly two-thirds of the patients (62%) felt that an injec-
tion of a cold FVIII product was more unpleasant than if it 
was at room temperature, and 74% of the patients “wait for 
their FVIII product to reach room temperature before injecting 
it”, with an average waiting time of 10 min. For these patients, 
storing FVIII in the refrigerator increased time of preparation. 
Patients who stored FVIII in the refrigerator reported an 
average time of 23 min for the preparation process, which 
included mixing FVIII with solvent, injection, and cleaning 
up. By comparison, patients storing FVIII at room tempera-
ture prepared their dose in around half the time (~12 min).
Although one-third (33%) of the patients considered the 
process of storing, preparing, and mixing the FVIII product 
disruptive to their daily routine, nearly half of them (46%) 
said it caused little or no disruption. However, patients who 
stored their FVIII product outside the refrigerator were much 
less likely to be affected by the process of storing, preparing, 
and mixing the product; nearly two-thirds of the patients 
(61%) said they experienced little or no disruption compared 
with 43% of the patients who refrigerated the product and 
reported no disruption (p0.05).
Patients were asked to select from a list of 14 emotional 
attributes describing how they felt when using their FVIII 
product in daily life. “Relaxed” was the only attribute 
showing a significant difference (p0.05) between patients 
who stored the product inside or outside the refrigerator (20% 
and 48%, for storage in the refrigerator and storage at room 
temperature, respectively).
satisfaction with taking FViii products
Patients were asked to indicate their overall level of satis-
faction by taking a FVIII product and with several features 
associated with their current product on a 5-point scale (1 [not 
at all satisfied] to 5 [extremely satisfied]).
Overall, one-third (32%) of the patients reported being 
highly satisfied (very/extremely) with their FVIII product, 
and 17% were found to be dissatisfied (Table 4). Highest 
satisfaction levels were achieved for “efficacy/prevention 
Table 4 satisfaction with FViii products
Aspect of satisfaction with the FVIII product All patients (n=200) % very/extremely satisfied
Very/extremely 
satisfied
Satisfied (Rather) 
dissatisfied
Storing FVIII in 
the refrigerator 
(n=169)
Storing FVIII 
outside refrigerator 
(n=31)
Overall satisfaction 32% 52% 17% 28% 52%*
Efficacy/prevention of bleeding 46% 45% 10% 43% 61%*
no skin reaction at the injection site 41% 49% 11% 40% 45%
storing the FViii product at home 30% 52% 19% 29% 35%
Procedure of mixing the product before injection 25% 39% 36% 22% 39%*
Flexibility of storing FViii outside or in the refrigerator 
depending on my personal needs
24% 35% 42% 18% 55%*
length of time the product can be stored outside the 
refrigerator
23% 38% 40% 19% 45%*
size of the vials with FViii 22% 60% 19% 18% 42%*
Broad range of available vial doses containing the right 
dose for me
22% 59% 20% 20% 32%
storage temperature 19% 52% 30% 15% 39%*
length of time the product is stable outside the 
refrigerator after mixing
18% 50% 33% 15% 35%*
Time for product to reach room temperature after 
taking out of the refrigerator before preparing
18% 64% 18% 18% n/a
size of the syringe 17% 61% 23% 15% 26%
storing the FViii product with me when i am away 
from home
16% 44% 41% 14% 29%*
Frequency of administration in prophylaxis 14% 42% 45% 12% 23%
size of package 13% 48% 39% 12% 16%
Taking all items needed for FViii treatment with me 
when i am traveling
11% 43% 47% 8% 23%*
Notes: *p0.05 (chi-square test). each aspect of satisfaction was rated on a 5-point scale: 1=not satisfied at all; 2=rather unsatisfied; 3=satisfied; 4=very satisfied; 5=extremely 
satisfied.
Abbreviations: FViii, factor Viii; n/a, not applicable.
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of bleeding” (46%), followed by “no skin reaction at the 
injection site” (41%). Satisfaction dropped considerably for 
other features: 30% were highly satisfied with “storing the 
FVIII product at home” and 25% with “procedure of mixing 
the product before injection”.
For several features (ie, “storage temperature”, “length of 
time the product is stable outside the fridge”, and “time for 
product to reach room temperature”), 20% of the patients 
were highly satisfied. “Frequency of administration” and 
“taking all items needed for FVIII treatment with me when 
I am traveling” were also concerns for most of the patients.
Overall satisfaction was found to be significantly higher 
among patients who stored their FVIII product at room tem-
perature compared with those who stored it in the refrigerator 
(Table 4). Storage had a significant effect on satisfaction 
levels for specific features of FVIII treatment related to flex-
ibility. For example, significant differences in patient groups 
were observed for “flexibility of storing FVIII outside or in the 
fridge depending on my personal needs”, “length of time the 
product can be stored outside the fridge”, “storage tempera-
ture”, “length of time the product is stable outside the fridge 
after mixing”, and “storing the FVIII product with me when 
I am away from home”. In addition, patients storing FVIII 
outside the refrigerator were more often satisfied with efficacy 
compared with those who stored it in the refrigerator.
restrictions on daily life
Patients were asked to rate their current FVIII product in 
terms of restriction of activities, using a scale of 1=“not 
restricted at all” and 4=“strongly restricted” (Table 5).
Most of the patients (76%) stated that their participation 
in sports was restricted to some extent and 23% found it 
“strongly restricted” (Table 5). Traveling away from home 
for 1 week was also likely to be restricted, as was traveling 
in hot countries, short trips, and any airline travel. Morning 
and evening routines were also affected, although to a lesser 
extent. In addition, patients who usually stored FVIII product 
in their refrigerator more frequently reported restrictions 
compared with those who stored it at room temperature.
Desired improvements to FViii products/
unmet needs
An open-ended question invited all patients to describe two 
improvements to their FVIII product that would make their 
life with hemophilia easier. The most commonly desired 
improvements were “reduced frequency of administration” 
(53%), “improved mode of administration” (47%), and 
“easier storage” (33%).
“Reduced frequency of administration” was particularly 
relevant to prophylactic users of FVIII products: 61% of them 
had mentioned it, compared with 30% of on-demand users.
conjoint analysis: relative impact of 
attributes on product choice
Overall, “origin of FVIII” had the highest impact on 
product choice (Figure 1), followed by “storage flexibility 
(temperature)” and “reconstitution device”. “Frequency of 
administration in prophylaxis”, “storage flexibility (shelf 
life)”, and “stability out of fridge after mixing” had less of 
an impact on preference. Three aspects of storage flexibility 
Table 5 restriction of activities in daily life by injecting FViii
Activities All patients (n=200) % at least somewhat restricted
Not 
restricted 
at all
(Somewhat) 
restricted
Strongly 
restricted
Storing FVIII in 
the refrigerator 
(n=169)
Storing FVIII 
outside refrigerator 
(n=31)
sports activities 24% 54% 23% 80%* 52%
Traveling for 1 week or longer 29% 66% 5% 75%* 52%
Traveling in countries where it is extremely warm 36% 53% 12% 66% 55%
Traveling by airplane (airport security) 41% 51% 9% 63%* 42%
leisure activities outside my home 46% 47% 7% 53% 58%
longer trips in a car or on a train 48% 50% 3% 56%* 32%
short trips between 2 days and 1 week 48% 50% 3% 54% 39%
Work trips/business trips 52% 46% 2% 49% 45%
sleepovers/overnight visits at friends or relatives 58% 40% 2% 41% 45%
getting ready in the morning 62% 38% 1% 40% 32%
Participating in social activities with other people 64% 35% 2% 36% 39%
My evening routine before i go to bed 66% 34% 0% 37%* 16%
The time i spend with my partner or family members 76% 23% 1% 25% 19%
Notes: *p0.05 (chi-square test). each aspect of restriction was rated on a 4-point scale: 1=not restricted at all; 2=somewhat restricted; 3=restricted; 4=strongly 
restricted.
Abbreviation: FViii, factor Viii.
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(ie, storage temperature, shelf life when FVIII is stored out 
of fridge, and stability out of fridge after mixing) had dif-
ferent impacts on product choice, with storage temperature 
(2°C–8°C vs 25°C vs 30°C vs 40°C) having the great-
est effect (Figure 2).
The contribution of individual attributes to product choice 
depended on the use of FVIII product. For instance, although 
“frequency of administration in prophylaxis” had an impact 
of only 17%, the difference between twice or thrice weekly 
administration in prophylaxis was slightly more important 
to those patients who currently use FVIII for prophylaxis 
(19% impact on preference).
It is important to note that, due to insufficient data, options 
in dosage frequency excluded once-weekly administration, 
which presumably would have been more of a driver of 
choice than either twice or thrice per week. The reason for 
its exclusion was that, at the time of the study, there were 
insufficient clinical trial data to demonstrate that once-weekly 
prophylaxis with FVIII has the same efficacy as administra-
tion of twice or thrice per week.16
Discussion
This study investigated the use of FVIII products by patients 
and assessed the impact of various product features on prod-
uct choice, specifically the importance of storage flexibility 
of FVIII products in daily life.
Challenges of prophylactic personalized treatments,17 
including frequency of infusions needed to maintain factor 
levels 1%, patient adherence to medication, physical 
activity, reliable intravenous access, and quality of life, 
have been identified in recent years.18 Results from this 
study, particularly those on patient satisfaction and unmet 
needs, indicate that most patients with hemophilia A are 
satisfied with efficacy and safety. However, 40% of the 
patients were not satisfied with administration frequency 
and 40% of the patients were dissatisfied with various 
aspects of storage.
Travel behavior and leisure activities clearly support 
the conclusion that patients with hemophilia A are part of 
an active and mobile society, and when away from home 
they have to carry items needed for reconstitution and 
administration of the product. This was substantiated by 
the finding that a considerably high proportion of patients 
were dissatisfied with several aspects of storing FVIII in 
a refrigerator.
Most of the patients stored FVIII in the refrigerator at 
home, and believed that it should always be stored in this 
way. This finding strongly suggests that patients are unaware 
that FVIII may be safely stored outside the refrigerator at 
room temperature (usually up to 25°C) for a limited number 
of months. The lack of awareness regarding storage tem-
perature was recently demonstrated in another study, where 
only 13% of the patients with hemophilia knew the storage 
temperature.19
A subgroup analysis showed several differences between 
the two groups of patients (storing vs not storing FVIII in the 
refrigerator). Compared with those patients who stored their 
FVIII product in the refrigerator, a significantly greater per-
centage who stored it outside the refrigerator were highly 
satisfied both overall and when traveling. Furthermore, they 
2ULJLQRI)9,,,SODVPDGHULYHGYVUHFRPELQDQW
6WRUDJHIOH[LELOLW\WHPSHUDWXUH5HFRQVWLWXWLRQGHYLFH
)UHTXHQF\RIDGPLQLVWUDWLRQLQSURSK\OD[LV
6WDELOLW\RXWRIIULGJHDIWHUPL[LQJ
6WRUDJHIOH[LELOLW\VKHOIOLIH






Figure 1 relative impact of the attributes on product choice.
Abbreviation: FViii, factor Viii.
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none of the patients in the sample stored their FVIII prod-
uct outside the refrigerator, which may have been related 
to climatic factors. It is also possible that Latin American 
patients had a lower socioeconomic status that is reflected 
by a lower travel frequency, suggesting that their satisfaction 
with travel-related aspects could be a demographic artifact. 
However, between Latin American patients and patients 
living in Europe/Japan, the travel frequency did not differ 
significantly regarding average number of travels per year 
(Latin America: 10.3 travels; Europe/Japan: 10.5 travels). 
Nevertheless, the subgroup of patients (n=31) storing FVIII 
at room temperature was too small to draw firm conclusions 
and further studies are required to investigate the impact of 
storage on patient satisfaction and preference.
Results from the conjoint analysis, in which all 200 patients 
were asked to select their preferred product attributes, showed 
that the most powerful driver of product choice was “origin 
traveled more frequently; spent less time to prepare and mix 
FVIII; and found storage, preparation, and mixing their FVIII 
to be less disruptive.
However, these observed associations may not be truly 
linked to causality. For example, frequent traveling could be 
the reason for storing FVIII product at room temperature. The 
same applies to other associations observed in this study such 
as that of a high restriction of sports activities in the group of 
patients who stored FVIII in their refrigerator. These associa-
tions could have been caused by other “hidden” variables, 
such as age, education, socioeconomic status, or anxiety levels 
regarding the use of FVIII. Indeed, “relaxed” was the only 
emotional attribute distinguishing both patient groups.
Interestingly, region/country of origin and travel fre-
quency were the only demographic variables to show a 
significant difference between patients who stored the 
product inside or outside the refrigerator. In Latin America, 
Figure 2 effect of attribute levels on product choice: part-worth utilities.
Notes: aMix FViii with 2 connected vials. One vial contains FViii powder, and the other contains solvent. Then put the mixed factor into a syringe connected with the vials.
Abbreviation: FViii, factor Viii.
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of FVIII”. Importantly, patients had a preference for recom-
binant products. Nowadays, recombinant coagulation FVIII 
products are considered safer than plasma-derived FVIII in 
terms of transmission of blood-borne pathogens.20,21
Interestingly, although most of the patients (85%) stored 
their FVIII product in the refrigerator, the second strongest 
driver of product choice was “storage flexibility (tempera-
ture)”. This contradiction in findings may be explained by 
the fact that most patients were unaware that current FVIII 
products can be stored safely outside the refrigerator.
Genetic engineering of new recombinant products aims to 
improve some specific therapeutic aspects, such as immuno-
genicity, neoantigenicity, and stability, and overcome limi-
tations of the manufacturing process.22 From a physician’s 
perspective, the clinical use of new drugs should encompass 
several variables, including, if possible, a convenient product 
administration.23 In the current survey, “frequency of admin-
istration in prophylaxis” was much less of a driver of choice 
than may have been expected from previous studies.13,15 
Nevertheless, the overall results from this study support the 
premise that patients prefer to have fewer injections without 
compromising efficacy.
Conclusion
This study provides clear evidence that most of the patients 
with hemophilia A were unaware that currently available 
FVIII products can be stored safely outside the refrigerator. 
If the result is representative of the worldwide hemophilia A 
population, then it is reasonable to conclude that current 
storage practices are not aligned with those of modern FVIII 
products, which can be stored safely outside the refrigerator, 
but at specified temperatures and with limited shelf life. When 
patients were informed of this possibility, storage of FVIII 
products outside the refrigerator was found to be the second 
highest driver of product choice if product efficacy, safety, 
and administration frequency were maintained.
From a physician’s perspective, adherence to treatment is 
essential for an accurate clinical evaluation of breakthrough 
bleeding during prophylaxis.24–26 Therefore, behavioral tech-
niques need to be implemented, with better communication 
from health care providers to explain product storage.27
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